Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 61.43
(-1.22%)
CNY 61.43
(-1.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.34 Billion CNY | 19.47% |
| 2022 | 2.8 Billion CNY | 135.51% |
| 2021 | 1.18 Billion CNY | 209.0% |
| 2020 | 384.94 Million CNY | -63.39% |
| 2019 | 1.05 Billion CNY | 62.34% |
| 2018 | 647.65 Million CNY | 94.54% |
| 2017 | 332.92 Million CNY | 67.19% |
| 2016 | 199.12 Million CNY | -27.41% |
| 2015 | 274.3 Million CNY | -0.65% |
| 2014 | 276.08 Million CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.65 Billion CNY | 9.09% |
| 2024 Q2 | 4.07 Billion CNY | 11.56% |
| 2024 Q3 | 3.4 Billion CNY | -5.43% |
| 2023 Q2 | 3.31 Billion CNY | 8.93% |
| 2023 Q4 | 3.34 Billion CNY | -9.18% |
| 2023 FY | 3.34 Billion CNY | 19.47% |
| 2023 Q3 | 3.68 Billion CNY | 11.21% |
| 2023 Q1 | 3.04 Billion CNY | 8.58% |
| 2022 Q3 | 2.86 Billion CNY | 19.19% |
| 2022 Q2 | 2.4 Billion CNY | 35.63% |
| 2022 Q4 | 2.8 Billion CNY | -2.29% |
| 2022 Q1 | 1.77 Billion CNY | 49.09% |
| 2022 FY | 2.8 Billion CNY | 135.51% |
| 2021 Q3 | 951.82 Million CNY | 61.39% |
| 2021 FY | 1.18 Billion CNY | 209.0% |
| 2021 Q2 | 589.76 Million CNY | 6.68% |
| 2021 Q4 | 1.18 Billion CNY | 24.97% |
| 2021 Q1 | 552.81 Million CNY | 43.61% |
| 2020 Q1 | 1.39 Billion CNY | 33.11% |
| 2020 Q3 | 294.12 Million CNY | -82.49% |
| 2020 FY | 384.94 Million CNY | -63.39% |
| 2020 Q4 | 384.94 Million CNY | 30.88% |
| 2020 Q2 | 1.67 Billion CNY | 20.03% |
| 2019 Q2 | 903.49 Million CNY | 24.43% |
| 2019 Q4 | 1.05 Billion CNY | 58.66% |
| 2019 FY | 1.05 Billion CNY | 62.34% |
| 2019 Q1 | 726.09 Million CNY | 12.11% |
| 2019 Q3 | 662.67 Million CNY | -26.65% |
| 2018 Q4 | 647.65 Million CNY | 77.04% |
| 2018 FY | 647.65 Million CNY | 94.54% |
| 2018 Q3 | 365.82 Million CNY | -11.25% |
| 2018 Q2 | 412.19 Million CNY | -17.91% |
| 2018 Q1 | 502.12 Million CNY | 50.82% |
| 2017 FY | 332.92 Million CNY | 67.19% |
| 2017 Q1 | 144.34 Million CNY | -27.51% |
| 2017 Q2 | 214.79 Million CNY | 48.81% |
| 2017 Q4 | 332.92 Million CNY | 11.29% |
| 2017 Q3 | 299.15 Million CNY | 39.27% |
| 2016 Q4 | 199.12 Million CNY | 21.94% |
| 2016 Q3 | 163.3 Million CNY | -24.98% |
| 2016 Q2 | 217.68 Million CNY | -19.5% |
| 2016 FY | 199.12 Million CNY | -27.41% |
| 2016 Q1 | 270.42 Million CNY | -1.41% |
| 2015 Q2 | 19.12 Million CNY | 179.33% |
| 2015 Q3 | 188.04 Million CNY | 883.15% |
| 2015 Q4 | 274.3 Million CNY | 45.87% |
| 2015 Q1 | 6.84 Million CNY | -97.52% |
| 2015 FY | 274.3 Million CNY | -0.65% |
| 2014 Q1 | 49.2 Million CNY | 0.0% |
| 2014 Q4 | 276.08 Million CNY | 0.88% |
| 2014 Q3 | 273.66 Million CNY | 455.64% |
| 2014 Q2 | 49.25 Million CNY | 0.09% |
| 2014 FY | 276.08 Million CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.29 Billion CNY | 22.021% |
| Dirui Industrial Co.,Ltd. | 714.1 Million CNY | -368.639% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | -194.691% |
| Medicalsystem Biotechnology Co., Ltd. | 108.17 Million CNY | -2993.784% |
| Maccura Biotechnology Co.Ltd | 665.16 Million CNY | -403.122% |
| Guangzhou Wondfo Biotech Co.,Ltd | 599.53 Million CNY | -458.193% |
| Guangdong Hybribio Biotech Co.,Ltd. | 56.65 Million CNY | -5807.22% |
| BGI Genomics Co., Ltd. | 1.09 Billion CNY | -205.233% |
| Amoy Diagnostics Co., Ltd. | 108.34 Million CNY | -2988.788% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 374.62 Million CNY | -793.322% |